AACR 2024 | Clinical advances in the management of gliomas

Patrick Wen, MD, Dana-Farber Cancer Institute, Boston, MA, highlights recent clinical advances in the management of gliomas. The Phase III INDIGO trial (NCT04164901) tested vorasidenib, an inhibitor of mutant isocitrate dehydrogenase, common in grade 2 gliomas. The Phase II FIREFLY-1 trial (NCT04775485) targets BRAF mutations, the most common oncogenic drivers in pediatric low-grade gliomas, with type II RAF inhibitor tovorafenib. Both treatments are seeking FDA approval in 2024, and promise groundbreaking treatments for previously hard to treat gliomas. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.